---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030771"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:58:26.962017+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oncocyte reports Q2 revenue $104K, loss $0.36/sh; launches GraftAssure at two centers

## Summary
- Revenue of $104K from pharma services; operating expenses $4.7M; loss from ops $4.5M ($0.36/sh).
- GraftAssure RUO assay used at two transplant centers in U.S. and Southeast Asia in July 2024.
- Sales funnel represents centers covering ~25% of annual U.S. transplant volumes (11,000+ transplants).
- Appointed Andrea James as CFO; she previously led IR at Axon and helped raise >$550M in equity.
- Cash & equivalents $11.0M at June 30, up $3.7M sequentially; includes $1.7M restricted cash.

## SEC filing metadata
- accession: 0001493152-24-030771
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224030771/0001493152-24-030771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224030771/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030771
- JSON: https://secwatch.observer/filing/0001493152-24-030771.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.